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Abstract
Experimental studies in ischemia–reperfusion and sepsis indicate
that activated protein C (APC) has direct anti-inflammatory effects
at a cellular level. In vivo, however, the mechanisms of action have
not been characterized thus far. Intravital multifluorescence
microscopy represents an elegant way of studying the effect of
APC on endotoxin-induced leukocyte–endothelial-cell interaction
and nutritive capillary perfusion failure. These studies have clarified
that APC effectively reduces leukocyte rolling and leukocyte firm
adhesion in systemic endotoxemia. Protection from leukocytic
inflammation is probably mediated by a modulation of adhesion
molecule expression on the surface of leukocytes and endothelial
cells. Of interest, the action of APC and antithrombin in endotoxin-
induced leukocyte–endothelial-cell interaction differs in that APC
inhibits both rolling and subsequent firm adhesion, whereas
antithrombin exclusively reduces the firm adhesion step. The
biological significance of this differential regulation of inflammation
remains unclear, since both proteins are capable of reducing
sepsis-induced capillary perfusion failure. To elucidate whether the
action of APC and antithrombin is mediated by inhibition of
thrombin, the specific thrombin inhibitor hirudin has been examined
in a sepsis microcirculation model. Strikingly, hirudin was not
capable of protecting from sepsis-induced microcirculatory
dysfunction, but induced a further increase of leukocyte–
endothelial-cell interactions and aggravated capillary perfusion
failure when compared with nontreated controls. Thus, the action
of APC on the microcirculatory level in systemic endotoxemia is
unlikely to be caused by a thrombin inhibition-associated anti-
coagulatory action.
Introduction
Alongside antithrombin and C1-esterase inhibitor, activated
protein C (APC) represents an important coagulatory inhibitor
in humans [1]. The zymogen protein C is activated by the
thrombin–thrombomodulin complex to give APC, whose
anticoagulatory activity is conferred primarily by its ability to
inactivate Factor Va and VIIIa [2]. APC is also known to
increase fibrinolysis [3]. In human sepsis, disruption of the
normal balance between coagulation and fibrinolysis has been
characterized by its correlation with organ dysfunction and
increased mortality [1,4]. Thus, acquired protein C deficiency
is associated with increased morbidity and mortality in patients
with severe sepsis and septic shock [5,6].
Direct anti-inflammatory properties of APC that have been
characterized  in vitro were considered independent from
coagulatory inhibition [7-9]. Thus, an experimental APC
application is capable of blocking the lethal effects of
Escherichia coli-induced septic disseminated intravascular
coagulation [10], but also improves outcome in meningo-
coccal-induced septic shock [11]. Also, APC effectively
prevents endotoxin-induced pulmonary vascular injury [12].
Conversely, the application of antiprotein-C antibodies
produces higher sensitivity towards defined endotoxin stimuli
and increases mortality [12]. Because organ dysfunction and
animal survival are not improved by the administration of other
substances with comparable anticoagulant effects, it has
been suggested that the action of APC is not solely
dependent upon its anticoagulatory properties [12]. Although
there is in vitro evidence from cell-culture studies to show
that APC blocks leukocytic adhesion to the endothelium [13],
the in vivo mechanisms of APC-related anti-inflammatory and
microcirculatory action have not been completely elucidated
thus far.
Before discussing the role of APC on the microcirculation in
sepsis, we will provide some information on the role of the
microcirculation in the development of organ dysfunction and
coagulatory failure.
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Role of leukocyte–endothelial-cell
interactions and capillary perfusion failure in
the development of septic organ failure and
coagulatory failure
Leukocyte–endothelial-cell interaction is essential for an
effective defense against bacterial invasion [14]. However,
leukocytic activation is associated with an increased
proinflammatory immune response [15], which is caused by
an increased release of inflammatory cytokines, including
tumor necrosis factor-α, interleukin-1β and interleukin-8,
which initiate generalized neutrophil (polymorphonucleocyte)
activation [16]. This release of mediators, together with the
generalized activation and sequestration of neutrophils, may
contribute to the widespread microvascular injury and
subsequent endothelial damage observed in sepsis [17]. The
migration of polymorphonucleocytes to inflamed tissue is
primarily dependent on the induction of secondary adhesion
molecules that are expressed on leukocytes and activated
vascular endothelium [18,19]. This migration, along with the
subsequent release of oxygen radicals and other toxic
substances, represents a central step in the development of
multiple organ failure [20].
The endothelial switch from anticoagulant to procoagulant
during sepsis is thought to be related to the cytokine-
mediated expression of endothelial adhesion molecules (e.g.
E-selectin, P-selectin, intercellular adhesion molecule-1) [21]
and increased tissue factor production by monocytes and
endothelial cells [22]. Generalized activation of coagulation
can be quantified by the measurement of endogenous
coagulatory inhibitors. Additionally, endotoxins are, per se,
known to directly generate an environment favoring
coagulation processes by activating the extrinsic coagulation
pathway via monocytic tissue factor expression [23]. Thus,
the concept of exogenous application of natural coagulatory
inhibitors has been evaluated in terms of reducing systemic
activation of leukocytes and endothelial cells [9,24].
Action of APC on the microcirculation in
ischemia–reperfusion injury
Although the anticoagulatory effects of APC have been
extensively investigated during the last two decades, only a
few studies have analyzed the actions of APC on the
microcirculation during ischemia–reperfusion. To study
ischemia–reperfusion injury in a clinically relevant setting,
models of warm ischemia have been extensively used in
rodents. In a rat model, APC has been administered
intravenously before the induction of warm ischemia [25].
Interestingly, the histological changes in renal tissue
observed in control animals after noncrushing microvascular
clamping for 60 min were almost completely absent after
prophylactic APC administration in this model. These APC
effects on organ structure corresponded to a highly effective
preservation of renal tissue blood flow that was significantly
decreased after ischemia–reperfusion in controls. Also,
changes in vascular permeability were prevented effectively
by APC application [25]. Since these postischemic
alterations were only significantly inhibited by APC and not a
specific Factor Xa inhibitor or heparin, the authors suggested
that APC protects against ischemia–reperfusion-induced
renal injury not by inhibition of coagulation abnormalities but
rather by direct inhibition of leukocyte activation.
Another group has also described a combination of anti-
inflammatory and anticoagulatory actions of APC during renal
ischemia reperfusion that provided microvascular protection
[26]. In this model, leukopenia effectively reduced ischemia–
reperfusion-induced renal injury. Since leukocytes were,
therefore, thought to be of central importance in the
development of organ injury, the authors hypothesized that
APC inhibits neutrophil adhesion, thereby attenuating the
release of neutrophil elastase and oxygen radicals, both of
which increase vascular permeability. However, since neither
group had the opportunity to evaluate the actions of APC on
the microcirculation in vivo, their conclusions remain
speculative.
The effects of APC on ischemia–reperfusion-induced organ
damage have also been evaluated in hepatic tissue:
Yamaguchi and colleagues investigated the role of APC in a
model of ischemia–reperfusion-induced injury in rat livers
[27]. Before inducing liver ischemia by portal vein cross-
clamping for 30 min, APC was intravenously applied. The
serum concentrations of cytokine-induced neutrophil
chemoattractants (CINC) were significantly reduced by APC
application. Simultaneously, an observed lowering of
myeloperoxidase activity in hepatic tissue during APC
application indicated a lesser accumulation of neutrophils in
the liver. Of interest, an inactive derivative of Factor Xa, which
represents a selective inhibitor of thrombin generation, was
also effective in decreasing CINC concentrations and could
prevent leukocyte accumulation. This indicated that, in this
case, postischemic hepatic microcirculatory disturbances
were induced by microthrombotic occlusion in a thrombin-
dependent mechanism.
Action of APC on the microcirculation during
endotoxemia
APC has been used in several sepsis models to modulate the
sepsis-induced proinflammatory response. Thus, a
prospective, blinded, placebo-controlled trial has been
performed in a rabbit model of meningococcal endotoxin-
induced shock [11]. APC was administered as a continuous
infusion to prevent sepsis-induced cardiocirculatory failure.
Strikingly, APC administration could not prevent an
endotoxin-mediated decrease in mean arterial pressure and
an increase in heart rate. However, despite lacking any effect
on macrohemodynamics, survival was significantly improved
from 45% to 75%. The authors hypothesized that APC had
an effect on the microcirculation since the expected macro-
hemodynamic changes could not be characterized in their
experiment. In a model of endotoxin-induced acute respiratoryS35
distress syndrome, APC attenuated endotoxin-induced
pulmonary vascular injury, probably by the significant
reduction of endotoxin-induced pulmonary leukocyte
infiltration [12]. In light of these findings, it is highly likely that
APC also has a direct effect on the microcirculation during
endotoxemia. However, none of these models allowed the
direct visualization of the microcirculation and, thus, the study
of APC effects on microcirculatory dysfunction.
To evaluate the effects of APC on the microcirculation in vivo
during endotoxemia, our group tested APC in a sepsis model
that permitted observation of the microcirculation under non-
invasive, normotensive conditions [28]. Endotoxin induced a
massive increase in leukocyte accumulation in precapillary
arterioles and postcapillary venules, with a maximal effect
observed after 8 hours (Fig. 1). Macrohemodynamic distur-
bances could be excluded by careful analysis of macro-
hemodynamic and microhemodynamic parameters in this
model [29]. APC significantly reduced endotoxin-induced
leukocyte rolling in arterioles and venules (Fig. 2). Moreover,
the next step in the leukocyte–endothelial-cell interaction
(namely, leukocyte adherence) was also significantly inhibited
in arterioles and venules (Fig. 3) [30]. In addition, endotoxin-
mediated deterioration of microvascular perfusion was
counteracted effectively by intravenous APC administration.
Since leukocyte rolling is predominantly mediated by
adhesion molecules of the selectin family, the reduction of
leukocyte rolling by APC may indicate a modulation of
selectin expression on leukocytes and the endothelium.
This view corresponds to in vitro data obtained by vascular
endothelial cell culturing, where human plasma-derived and
human cell-produced protein C blocked E-selectin-mediated
cell adhesion to the endothelium [13]. From our in vivo study,
we concluded that it is highly likely that a specific anti-
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Figure 1
Visualization of leukocyte sticking in the arteriole by intravital
fluorescence microscopy (performed using a charge-coupled device
camera before and after lipopolysaccharide administration).
Representative arterioles (a) before and (b) 8 hours after endotoxin
application. Note that leukocytes also adhere to the endothelial lining
of arterioles during endotoxemia despite high flow conditions.
Figure 2
Effect of activated protein C (APC) on lipopolysaccharide (LPS)-
induced (a) arteriolar and (b) venular leukocyte rolling. The APC group
contained animals (n = 8) that received LPS (2 mg/kg) and APC
(24 µg/kg per 8 hours intravenously). The control group contained
vehicle-treated animals (n = 7) that received LPS (2 mg/kg) only.
*P < 0.05, APC animals versus lipopolysaccharide-treated controls
(unpaired Student’s t-test). §P < 0.05, intergroup differences from
baseline (paired Student’s t-test). Data are the mean ± standard error
of mean. Reproduced with permission [30].S36
inflammatory interaction between APC and the endothelium
is responsible for microcirculatory protection. Since thrombin
inhibition alone obviously does not reduce endotoxin-
mediated leukocyte rolling and adhesion [31], anticoagulatory
APC activities (namely, inhibition of Factors Va and VIIIa that
would result in less thrombin formation) are probably unlikely
to be responsible for the protective effects of APC on the
microcirculation during endotoxemia. Table 1 shows an
overview of the differential effects of the anticoagulants APC,
antithrombin, and hirudin (a specific thrombin inhibitor) on
different steps in the leukocyte–endothelial-cell interaction
and capillary perfusion in septic disorders.
Conclusion
The protein C and antithrombin anticoagulant pathways
represent major mechanisms in controlling microvascular
dysfunction during ischemia–reperfusion injury and sepsis.
Local and systemic antithrombin and APC deficiencies
augment the proinflammatory response and thereby contri-
bute to increased leukocyte–endothelial-cell interactions and
capillary perfusion failure. The obvious reduction in
endogenous inhibitors represents the rationale for exogenous
coagulatory inhibitor treatment. APC and antithrombin have
been used in experimental models to reduce ischemia–
reperfusion injury and to improve septic disorders with
comparable efficacy. The exact molecular mechanisms of
action of APC and antithrombin during ischemia–reperfusion
and endotoxemia remain unclear. However, it is highly likely
that a specific anti-inflammatory interaction with the endo-
thelium and leukocytes is responsible for APC-related
microcirculatory protection. Thus, APC treatment using a
dose corresponding to that used in the Recombinant Human
Activated Protein C Worldwide Evaluation in Severe Sepsis
(PROWESS) study in vivo reduced the extent of transient
leukocyte–endothelial-cell interactions (leukocyte rolling) and
inhibited subsequent firm leukocyte adherence (leukocyte
sticking) to the endothelium. Both mechanisms lessened
endotoxin-mediated microvascular perfusion injury. These
microcirculatory APC actions may also be used under clinical
situations involving microcirculatory disorders. From the
majority of experimental studies presented here, there is,
however, no evidence to support antithrombotic
(anticoagulatory) therapy specifically targeting thrombin
inhibition, since thrombin inhibitors (e.g. hirudin and heparin)
do not provide comparable protection of the microcirculation,
but, on the contrary, may even aggravate sepsis-mediated
disorders.
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